Completion axillary lymph node dissection for the identification of pN2–3 status as
an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the
randomised, phase 3 SENOMAC trial
de, Boniface J.; Appelgren, M.; Szulkin, R.; Alkner, S.; Andersson, Y.; Bergkvist, L.; Frisell, J.; Gentilini, O.D.; Kontos, M.; Kühn, T.; Lundstedt, D.; Offersen, B.V.; Bagge, R.O.; Reimer, T.; Sund, M.; Christiansen, P.; Rydén, L.; Tvedskov, T.F.; SENOMAC, Trialists' Group